BREAKING
AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 15 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 6 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 15 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 6 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago
ADVERTISEMENT
Market News

Abbott Laboratories achieves double-digit earnings growth

Abbott (NYSE: ABT), we’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that […]

January 22, 2026 1 min read

Abbott (NYSE: ABT), we’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that […]

· January 22, 2026

Abbott (NYSE: ABT), we’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that our next breakthrough can lead to theirs.

Current Stock Price:

  • $120.73

Market Capitalization:

  • $209.9 billion
  • Enterprise Value (EV): $215.2 billion

Valuation:

  • Trailing P/E: 15.2
  • Forward P/E: 21.8
  • Indicates ABT’s earnings relative to its price are moderate compared with many large healthcare peers.
  • Growth-Adjusted Valuation
    • PEG Ratio: 2.26 (higher number suggests slower expected growth relative to current valuation).
  • Sales & Cash Flow Multiples
    • P/S (Price/Sales): ~4.8
    • P/B (Price/Book): ~4.1
    • P/FCF (Price/Free Cash Flow): ~30.4
    • EV/EBITDA: ~18.3